Efficacy and safety of adjuvant chemotherapy for locally advanced cervical cancer : A systematic review and meta-analysis
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND: Locally advanced cervical cancer (LACC) is generally treated using concurrent chemo-radiotherapy (CCRT); yet, the effectiveness of adjuvant chemotherapy (ACT) following CCRT remains controversial.
METHODS: The databases Embase, Web of Science, and PubMed were analyzed for relevant research. Primary endpoints included overall survival (OS) and progression-free survival (PFS).
RESULTS: Fifteen trials with 4041 patients were included. Pooled HRs for PFS and OS were 0.81 (95 % CI: 0.67-0.96) and 0.69 (95 % CI: 0.51-0.93), respectively. However, subgroup analyses indicated that in randomized trials and trials with larger sample sizes (n > 100) as well as ACT cycles ≤ 3, ACT was not linked with improved PFS and OS. Moreover, ACT induced a greater rate of hematologic toxicities (P < 0.05).
CONCLUSION: Higher quality of evidence suggests that ACT could not yield additional survival benefits for LACC; however, identifying high-risk patients who may benefit from ACT is required to design further clinical trials and better inform treatment decisions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:184 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 184(2023) vom: 09. Apr., Seite 103953 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Xiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant chemotherapy |
|---|
| Anmerkungen: |
Date Completed 03.04.2023 Date Revised 03.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2023.103953 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353953369 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353953369 | ||
| 003 | DE-627 | ||
| 005 | 20231226061156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2023.103953 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1179.xml |
| 035 | |a (DE-627)NLM353953369 | ||
| 035 | |a (NLM)36889613 | ||
| 035 | |a (PII)S1040-8428(23)00041-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Xiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of adjuvant chemotherapy for locally advanced cervical cancer |b A systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.04.2023 | ||
| 500 | |a Date Revised 03.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Locally advanced cervical cancer (LACC) is generally treated using concurrent chemo-radiotherapy (CCRT); yet, the effectiveness of adjuvant chemotherapy (ACT) following CCRT remains controversial | ||
| 520 | |a METHODS: The databases Embase, Web of Science, and PubMed were analyzed for relevant research. Primary endpoints included overall survival (OS) and progression-free survival (PFS) | ||
| 520 | |a RESULTS: Fifteen trials with 4041 patients were included. Pooled HRs for PFS and OS were 0.81 (95 % CI: 0.67-0.96) and 0.69 (95 % CI: 0.51-0.93), respectively. However, subgroup analyses indicated that in randomized trials and trials with larger sample sizes (n > 100) as well as ACT cycles ≤ 3, ACT was not linked with improved PFS and OS. Moreover, ACT induced a greater rate of hematologic toxicities (P < 0.05) | ||
| 520 | |a CONCLUSION: Higher quality of evidence suggests that ACT could not yield additional survival benefits for LACC; however, identifying high-risk patients who may benefit from ACT is required to design further clinical trials and better inform treatment decisions | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adjuvant chemotherapy | |
| 650 | 4 | |a Concurrent chemo-radiotherapy | |
| 650 | 4 | |a Locally advanced cervical cancer | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Fang, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yao |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xiaohua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shuixing |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Bin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 184(2023) vom: 09. Apr., Seite 103953 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:184 |g year:2023 |g day:09 |g month:04 |g pages:103953 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2023.103953 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 184 |j 2023 |b 09 |c 04 |h 103953 | ||